Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Liabilities (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Total Liabilities for 14 consecutive years, with $197.3 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 66.01% to $197.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $197.3 million through Dec 2025, down 66.01% year-over-year, with the annual reading at $197.3 million for FY2025, 66.01% down from the prior year.
  • Total Liabilities hit $197.3 million in Q4 2025 for Coherus Oncology, down from $428.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $845.4 million in Q1 2024 to a low of $197.3 million in Q4 2025.
  • Historically, Total Liabilities has averaged $591.0 million across 5 years, with a median of $588.1 million in 2021.
  • Biggest five-year swings in Total Liabilities: surged 82.9% in 2021 and later plummeted 66.01% in 2025.
  • Year by year, Total Liabilities stood at $581.6 million in 2021, then increased by 6.3% to $618.3 million in 2022, then skyrocketed by 33.12% to $823.0 million in 2023, then decreased by 29.47% to $580.5 million in 2024, then tumbled by 66.01% to $197.3 million in 2025.
  • Business Quant data shows Total Liabilities for CHRS at $197.3 million in Q4 2025, $428.7 million in Q3 2025, and $319.6 million in Q2 2025.